When it comes to emergency preparation, Houston buildings need to focus on communication and compliance, says this expert

Guest column

Houston buildings — old and new — need to think about their emergency communication compliance. Photo by Zview/Getty Images

Like most of us, I remember where I was when I learned that terrorists had crashed hijacked planes into the Twin Towers on September 11, 2001.

In addition to the high cost of civilian life, 412 firefighters, EMTs and police officers lost their lives — many the result of not receiving an order to evacuate. Many just did not get the order because the existing first responder radio system and private cellular services were too jammed with calls as a result of the emergency and as a result of damage to the buildings. We also saw the same lack of decent communications with law enforcement in the Mandalay Bay mass shooting in Las Vegas.

The lessons of the Twin Towers were not lost on the city of Houston and Harris County which require all new buildings to have a specially designed emergency responder radio system, or ERRS, installed which passes a rigorous testing procedure. Buildings over three stories, without a basement or over 50,000 square feet are not exempt but do not have to submit plans to the city. If the system is not designed properly, The city and county will not issue a certificate of occupancy. Repeated violations of an order to install an ERRS can result not only in fines and city tickets, but also in a referral to the district attorney's office to consider whether a felony level crime has occurred. It is not a trivial building code provision obviously.

Unfortunately, this ordinance is either not known or is not known well yet. I serve as the chairman of the Houston Tower Commission, am a former Houston council member and chairman of the Regulatory Affairs Committee, an attorney for almost 28 years, a law professor in legislation, and the owner of a professional design/build company involved in wireless electrical engineering and installation.

While I can't issue a formal advisory opinion on behalf of the city, on an industry level this is what businesses and commercial builders need to know:

  • Every building is different, and the systems are not off the shelf or cheap.
  • The publicly broadcast FirstNet signal, if being received throughout your building, does not exempt a building owner from compliance.
  • Compliance is not entirely based on the equipment installed, but primarily on results. Each floor of a covered building is divided in to 20 grids and each grid is tested to see if the signal strength is 95 dBm. If more than two consecutive grids fail, then the floor is divided into 40 grids and if four consecutive grids fail, the system must be redesigned.
  • The systems must be designed by an engineer utilizing iBwave software that should be submitted with your permit package. Again, these are not off the shelf products.
  • Because the systems are designed to work when a building is on fire, most cabling must be done with a fire resistant conduit, fiber or even fireproof antennas in certain jurisdictions.
  • Existing buildings are not required by code to install an ERRS unless they undergo a major renovation. However, a building owner can install one of the systems voluntarily.

It is the nature of the evolving world of wireless technology that our "smart buildings" of the future will be required to install technology of all sorts that allows for modern communications. Certain cities are already requiring new buildings to also install private wireless systems that allow you to use your private cell phone throughout your building. The correlation is clearly with sprinkler systems, the requirement for which is found in the same section of the fire code which requires an ERRS. Sprinkler systems were invented in 1872 but were not required by code until the 1960s. Amazingly, there are many cities that have not modernized their codes to require an ERRS in new buildings, including Dallas.

------

Rob Todd is the founder of Amplified Solutions and chair of the Tower Permit Commission for the city of Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings